

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

General Comments and Additional Information

Total Vol:

Source:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

002139 CEA

CEA		2.5	0.0-4.7 / ng/mL	Final	01
-----	--	-----	-----------------	-------	----

Nonsmokers <3.9

Smokers <5.6

Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

002253 AFP, Serum, Tumor Marker

AFP, Serum, Tumor Marker		<1.8	0.0-8.4 / ng/mL	Final	01
--------------------------	--	------	-----------------	-------	----

Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)

Values obtained with different assay methods or kits cannot be

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

This test is not interpretable in pregnant females.

002261 CA 19-9

CA 19-9		12	0-35 / U/mL	Final	01
---------	--	----	-------------	-------	----

Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

002303 Cancer Antigen (CA) 125

Cancer Antigen (CA) 125		14.0	Not Estab. / U/mL	Final	01
-------------------------	--	------	-------------------	-------	----

Roche Diagnostics Electrochemiluminescence Immunoassay (ECLIA)

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

010322 Prostate-Specific Ag

Patient Name:
Patient Phone:
Date of Birth (Age):
Sex:
Referring Dr (NPI #):
Patient ID:
Specimen ID:

Account Number:
Account Name:
Collection Date/Time:
Received Date/Time:
Reported Date/Time:

Result Name	Flag	Result	Range/Units	Status	Lab
-------------	------	--------	-------------	--------	-----

Prostate Specific Ag		1.3	0.0-4.0 / ng/mL	Final	01
----------------------	--	-----	-----------------	-------	----

Roche ECLIA methodology.

According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater.

Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Performing Lab

01 - Labcorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 92128-4108, (858) 668-3700, Galloway, Jenny R MD

For Inquiries, the physician may contact the performing lab.

END OF REPORT